Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer

Chong Kun Dang Pharmaceutical7 sites in 1 country44 target enrollmentAugust 2009

ConditionsAdvanced Solid Cancers

InterventionsCKD-810, Taxotere inj.

DrugsCKD-810, Taxotere inj.

Overview

Phase: Phase 1
Intervention: CKD-810, Taxotere inj.
Conditions: Advanced Solid Cancers
Sponsor: Chong Kun Dang Pharmaceutical
Enrollment: 44
Locations: 7
Primary Endpoint: Pharmacokinetics of CKD-810 and Taxotere inj.
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.

Detailed Description

This is a Phase III study designed to evaluate the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer. This study will also assess the safety of the docetaxel in advanced solid cancer patients.

Registry

clinicaltrials.gov

Start Date

August 2009

End Date

December 2010

Last Updated

15 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Chong Kun Dang Pharmaceutical

Eligibility Criteria

Inclusion Criteria

•Patient is greater than 18 years of age
•Advanced solid tumor
•locally advanced or metastatic breast cancer which docetaxel alone therapy was adequate
•locally advanced or metastatic non-small cell lung cancer which docetaxel alone therapy was adequate
•locally advanced or metastatic other malignant tumor which docetaxel alone therapy was adequate
•Patient has a life expectancy of at least 3 months
•Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
•Absolute neutrophil count ≥ 1,500/㎣
•Platelet count ≥ 100,000/㎣
•Hemoglobin ≥ 9.0g/dL

Exclusion Criteria

•If present, any active bacterial infection that have to parenteral antibiotic therapy. Patients may be included if their infection has resolved to totally or controlled state
•Brain metastasis with neurologic symptom
•History of unstable cardiac arrhythmia, congestive heart failure or myocardial infarction within 6 months
•Known to test positive for HIV or hepatitis B or C
•Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of study medication. (Patients may be included if the patients who need to intake the medication such as cimetidine was keep the same dose continuously at 1 cycle and 2 cycle)
•Peripheral neuropathy ≥ Grade 2
•known resistant or uncontrolled severe hypersensitivity to docetaxel
•History of hypersensitivity reaction to Polysorbate 80
•The female patients of pregnancy, breast feeding or childbearing potential. And the patients has not laboratory result or the result was a positive serum pregnancy test, also Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements. (In case of menopausal women, keeping menopause at least 12 months. All sexually active male patients must agree to use adequate methods of birth control throughout the study)
•Administration of any other tumor therapy, including chemotherapy, radiotherapy, and immunotherapy within 4 weeks before the beginning of study treatment. Patients may be included if the radiotherapy was conducted to relieve symptoms and that symptoms recovered to grade 1